PT  - JOURNAL ARTICLE
AU  - A. Omame
AU  - D. Okuonghae
TI  - A co-infection model for Oncogenic HPV and TB with Optimal Control and Cost-Effectiveness Analysis
AID  - 10.1101/2020.09.15.20195297
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.15.20195297
4099  - http://medrxiv.org/content/early/2020/09/27/2020.09.15.20195297.short
4100  - http://medrxiv.org/content/early/2020/09/27/2020.09.15.20195297.full
AB  - A co-infection model for oncogenic Human papillomavirus (HPV) and Tuberculosis (TB), with optimal control and cost-effectiveness analysis is studied and analyzed to assess the impact of controls against incident infection and against infection with HPV by TB infected individuals as well as optimal TB treatment in reducing the burden of the co-infection of the two diseases in a population. The co-infection model is shown to exhibit the dynamical property of backward bifurcation when the associated reproduction number is less than unity. Furthermore, it is shown that TB and HPV re-infection parameters (ϕp = 0 and σt = 0) as well as TB exogenous re-infection term (ε1 0) induced the phenomenon of backward bifurcation in the oncogenic HPV-TB co-infection model. The global asymptotic stability of the disease-free equilibrium of the co-infection model is also proven not to exist, when the associated reproduction number is below unity. The necessary conditions for the existence of optimal control and the optimality system for the co-infection model is established using the Pontryagin ‘s Maximum Principle. Uncertainty and global sensitivity analysis are also carried out to determine the top ranked parameters that drive the dynamics of the co-infection model, when the associated reproduction numbers as well as the infected populations are used as response functions. Numerical simulations of the optimal control model reveal that the intervention strategy which combines and implements control against HPV infection by TB infected individuals as well as TB treatment control for dually infected individuals is the most cost-effective of all the control strategies for the control and management of the burden of oncogenic HPV and TB co-infection.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.indexmundi.com/china/demographics\_profile Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Federal University of Technology Owerri, NigeriaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable https://www.indexmundi.com/china/demographics\_profile